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Stool testing based on tumour-derived markers might offer a promising approach for non-invasive colorectal cancer (CRC) screening.
The aim of this study was to estimate the potential of a new test for faecal tumour M2-PK to discriminate patients with CRC from a
large sample of unselected older adults. Faecal tumour M2-PK concentrations were determined in 65 CRC patients and in a
population-based sample of 917 older adults (median age: 65 and 62 years, respectively). Sensitivity and specificity of the test were
calculated at different cutoff values, and receiver-operating characteristic curves (ROC) were constructed to visualise the
discriminatory power of the test. The median (interquartile range) faecal tumour M2-PK concentration was 8.6Uml
 1 (2.8–18.0)
among CRC patients and o2Uml
 1 (o2–3.2; Po0.0001) in the population sample. At a cutoff value of 4Uml
 1, sensitivity (95%
confidence interval) was 85% (65–96%) for colon cancer and 56% (41–74%) for rectum cancer. Specificity (95% confidence interval)
was estimated to be 79% (76–81%). Given the comparatively high sensitivity of the tumour M2-PK stool test (especially for colon
cancer) and its simple analysis, the potential use of the test for early detection of CRC merits further investigation. Possibilities to
enhance specificity of the test should be explored.
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Colorectal cancer (CRC) is one of the leading causes of cancer-
related morbidity and mortality worldwide (Ferlay et al, 2004).
Even in countries where up-to-date therapeutic options are
available, more than 40% of CRC patients still die from the
disease within 5 years after diagnosis (Brenner, 2002; Brenner et al,
2005). As survival is considerably better for early, localised CRC
than for later stages and CRC might be prevented altogether by
detection and removal of precancerous lesions, enhanced screen-
ing will be of crucial importance for further progress in reducing
the burden of the disease.
Experience with faecal occult blood testing (FOBT) has shown
the possibility of reducing both incidence and mortality owing to
screening based on stool tests (Hardcastle et al, 1996; Mandel et al,
1999, 2000) and the advantages of this screening modality
regarding acceptability and practicality compared with invasive
screening options. However, given the limitations of FOBT, mainly
the inherently low sensitivity to detect precancerous or cancerous
lesions, there is still need for improvement. Therefore, the
development of stool tests with better performance characteristics
has become a focus of current research, both in the field of DNA-
based stool markers and in the field of protein-based stool
markers. For some of the new tests, preliminary results regarding
sensitivity and specificity are encouraging but evidence of the
performance of the new methods is mostly restricted to small-scale
investigations in the clinical setting (Haug and Brenner, 2005a).
A novel approach based on the detection of proteins in stool
derived from neoplastic colonocytes is the quantitative measure-
ment of faecal tumour M2-pyruvate kinase (tumour M2-PK).
Tumour M2-PK, an isoform of the glycolytic enzyme pyruvate
kinase, is found in proliferating tissues with a high capacity for
nucleic acid synthesis such as tumour cells (Mazurek et al,
2002a,b). The aim of this study was to estimate the potential of
testing for faecal tumour M2-PK to discriminate patients with CRC
from a large sample of unselected older adults.
MATERIALS AND METHODS
Study population
Stool samples were collected from 65 CRC patients before cathartic
preparation for surgery at the Department of Surgery, University
Hospital of Heidelberg, Germany. Samples from CRC patients were
collected between January 2003 and February 2005 and immedi-
ately frozen until laboratory analysis, which was performed in
March 2005. Data concerning age, gender, body mass index,
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scurrent smoking status, tumour stage, tumour location and
neoadjuvant therapy were abstracted from the hospital charts.
For comparison, stool samples were analysed from 917
participants aged 50–75 years of a large-scale population-based
cohort study (ESTHER¼‘Epidemiologische Studie zu Chancen der
Verhu ¨tung, Fru ¨herkennung und optimierten Therapie chronischer
Erkrankungen in der a ¨lteren Bevo ¨lkerung’), aimed to evaluate new
approaches to the prevention, early detection and therapy of
chronic diseases among older adults. ESTHER is conducted in
Saarland, a state located in SouthWest Germany, and recruitment
took place between June 2000 and December 2002. Details of the
study design have been reported elsewhere (Rothenbacher et al,
2005). Briefly, all participants (N¼9953) were asked to mail a stool
sample to the study centre for laboratory analyses (the date of
defecation and the date of receipt were documented) and to fill out
a standardised questionnaire containing information on socio-
demographic factors as well as detailed information regarding
potential risk factors for various forms of chronic diseases,
including CRC. In addition, medical data were recorded from the
charts of patients’ general practitioners. DNA was extracted from
stool of all participants. In case the original stool sample contained
more stool than the amount needed for DNA extraction, an
additional sample of unprocessed stool was preserved and frozen
until laboratory analysis, which was performed in March 2003. In
the present analysis, all ESTHER participants for whom an
additional sample of unprocessed stool was preserved were
included (N¼917). The study has been approved by local and
state Ethics Committees.
Laboratory analyses
For the quantitative measurement of tumour M2-PK, stool samples
were thawed and a special stick capturing 4mg of stool was loaded.
Stool samples of both the CRC patients and the ESTHER
participants were examined with the ScheBo
s Tumour M2-PK
test (ScheBo Biotech, Giessen, Germany), a sandwich enzyme-
linked immunosorbent assay (ELISA) based on two monoclonal
antibodies specific for tumour M2-PK. The test allows quantitative
measurement of tumour M2-PK in 4mg of stool with a lower
detection limit of 2Uml
 1. All analyses were carried out in a
central laboratory under standardised conditions.
Statistical analyses
The CRC patients were characterised with respect to age, gender,
body mass index, current smoking status, tumour stage, tumour
location and neoadjuvant therapy. The subsample of the ESTHER
study was described with respect to age, gender, body mass index,
family history of CRC and smoking status; the distribution of levels
of faecal tumour M2-PK among ESTHER participants was assessed
according to these factors.
To estimate performance characteristics regarding the detection
of CRC, the distribution of faecal tumour M2-PK concentrations
among participants of the ESTHER Study and among CRC patients
was compared. Sensitivity and specificity of the test were
calculated at a cutoff value of 4Uml
 1, the cutoff level proposed
by the manufacturer, and 95% confidence intervals were
determined based on the exact binomial distribution. In addition,
sensitivity and specificity were derived at a broad range of
alternative cutoff values and receiver-operating characteristic
curves (ROC) were constructed to visualise the discriminatory
power of the test. To estimate the area under the ROC, the curve
was linearly extrapolated beyond the lower detection limit of
2Uml
 1.
To assess the impact of different sample treatment between
ESTHER study participants (stool samples were mailed before
freezing) and CRC patients (stool samples were frozen immedi-
ately), sensitivity analyses were carried out based on the results of
stability testing (Haug et al, 2006). For that purpose, faecal tumour
M2-PK concentrations measured in ESTHER study participants
were corrected according to the duration of sample mailing to
estimate initial concentrations (the equation is given in Appendix
A). The duration of sample mailing was calculated from the date of
defecation and the date of receipt of the stool sample. On the basis
of corrected values, ROC analyses were repeated as described
above and compared to the ROC based on crude values.
RESULTS
In Table 1, the CRC patients, the subgroup of the ESTHER
participants included in this analysis and the whole ESTHER study
population are described with respect to age, sex, body mass index,
alcohol consumption, smoking status, family history of CRC (the
latter information was available for ESTHER study participants
only) and neoadjuvant treatment (CRC cases only). Median age
among CRC patients was 65 years and about one-third of the
patients were females. Median age in the subgroup of the ESTHER
study was 62 years, a slight majority were females. The subgroup of
the ESTHER study did not differ from the whole ESTHER study
population with respect to the distribution of age, sex, body mass
index, smoking status and family history of CRC.
The median (interquartile range) tumour M2-PK concentration
for the CRC patients was 8.6Uml
 1 (2.8–18.0) with a striking
difference between colon and rectum cancer (9.5Uml
 1, 6.2–18.4
and 5.5Uml
 1, o2–18.0, respectively). The median (interquartile
range) tumour M2-PK concentration in the subsample of the
ESTHER study was o2Uml
 1 (o2–3.2). The difference in
median tumour M2-PK levels in stool between ESTHER partici-
pants and both subgroups of CRC patients was highly statistically
significant (Po0.0001 for colon and rectum cancer, respectively;
see Figure 1).
In the patient sample, 60% of tumours were located in the
rectum (as the recruiting hospital was a referral centre for rectal
cancer patients). The most frequent tumour stage was T3 (34 out of
65). Information allowing Dukes’ classification was available for 48
patients. Twelve patients presented with Dukes’ stage A, 18 with
Dukes’ stage B, 12 with Dukes’ stage C and 6 with Dukes’ stage D.
At a cutoff value of 4Uml
 1, overall sensitivity (95% confidence
interval) was 68% (55–79%), with a clear difference between colon
cancer (85%) and rectum cancer (56%) (P¼0.02; see Table 2).
Sensitivity (95% confidence interval) by tumour size was 67%
(22–96%), 44% (20–70%), 71% (53–85%) and 100% (40–100%)
for T1–T4, respectively, and by Dukes’ stage it was 67% (35–90%),
61% (36–83%), 67% (35–90%) and 100% (54–100%) for Dukes’
stage A, B, C and D, respectively. As regards neoadjuvant therapy,
no impact on sensitivity could be observed.
Of the ESTHER study participants, 21% showed a positive test
result at the cutoff value of 4Uml
 1, that is, overall specificity was
79% (see Table 3). There was no clear association between age,
sex, body mass index or family history of CRC and a positive test
result. However, current smokers showed more frequently
increased levels of tumour M2-PK in stool compared to never
and former smokers (P¼0.003).
The results of the ROC analysis are shown in Figure 2 for both
colon and rectum cancer as well as for both forms of cancer
combined. With an area under the curve (AUC) of 0.789, the overall
discriminatory power of the test was good. The AUC for colon
cancer (0.857) was larger than the AUC for rectum cancer (0.744).
Taking into account potential degradation of tumour M2-PK in
samples from ESTHER study participants during mailing (stability
testing for tumour M2-PK in stool showed relative concentrations
of 73, 60, 49, 40 and 32% after 1, 2, 3, 4 and 5 days of storage at
room temperature, respectively; Haug et al, 2006), decreased the
estimate of specificity to 73% (70–76%) and shifted the ROC curve
to the right, resulting in a slightly smaller AUC (0.736).
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sDISCUSSION
In this study, performance characteristics for the tumour M2-PK
stool test, a novel approach aimed at detecting CRC in the
screening setting, were estimated by comparing tumour M2-PK
concentrations in CRC patients and in a large sample of unselected
older adults supposed to be healthy controls. With the cutoff level
at 4Uml
 1 (recommended by the manufacturer), overall sensiti-
vity for CRC was 68%. Albeit not perfect, this detection rate
compares superior to FOBT and to the results reported for several
DNA-based stool tests (Haug and Brenner, 2005a).
Colon cancer was detected with a remarkable sensitivity of 85%,
which was higher than for rectum cancer (56%). Correcting for the
unusually high proportion of rectal cancer patients in our sample
(60% in our sample vs 20% in population-based series of CRC
patients; Krebsregister Saarland, 2006) overall sensitivity for CRC
would be 79%. This estimate is in line with the finding of a recently
published prospective study reporting an overall sensitivity of 81%
(Shastri et al, 2006). As regards sensitivity by tumour stage, no
relevant difference could be observed between Dukes’ A, Dukes’ B
and Dukes’ C, but sensitivity was maximal for Dukes’ D. However,
given that in our study the number of cases per stage was rather
limited, larger studies are needed to estimate sensitivity by tumour
stage more precisely.
Specificity in terms of detecting CRC (ie, the denominator
comprises subjects who do not have CRC) in this study was
estimated to be about 79% (73% after correction for potential
degradation) at the proposed cutoff level of 4Uml
 1. This estimate
is based on tumour M2-PK concentrations determined in average-
risk subjects who did not undergo colonoscopy, that is, the current
status of the colon and rectum in this population sample serving as
control group was unknown. The putative false positive rate may
therefore comprise a small number of not yet diagnosed CRC
Table 1 Sociodemographic, lifestyle and further characteristics of CRC cases, the subgroup of ESTHER study participants included in this analysis and the
whole ESTHER study population
CRC patients
Subgroup of the
ESTHER study
N (%)
ESTHER study
population (overall)
N (%)
Colon cancer N (%) Rectal cancer N (%)
N¼26 N¼39 N¼917 N¼9953
Age group (years)
o50 4 (15) 3 (8) 0
50–54 3 (12) 5 (13) 165 (18) 1697 (17)
55–59 3 (12) 3 (8) 150 (16) 1689 (17)
60–64 3 (12) 9 (23) 263 (29) 2704 (27)
65–69 6 (23) 8 (21) 194 (21) 2279 (23)
X70 7 (27) 11 (28) 142 (16) 1565 (16)
Gender
Females 9 (35) 14 (36) 525 (57) 5469 (55)
Males 17 (65) 25 (64) 392 (43) 4484 (45)
Body mass index (kgm
 2)
p25 7 (27) 23 (61) 243 (27) 2706 (28)
425–30 12 (46) 11 (29) 398 (44) 4566 (46)
430 7 (27) 4 (11) 262 (29) 2564 (26)
Current smoking status
Non-smoker 23 (88) 33 (87) 742 (83) 8053 (83)
Smoker 3 (12) 5 (13) 154 (17) 1652 (17)
Family history of CRC
At least 1 first
degree relative
with CRC
NR NR 68 (7) 904 (9)
Neoadjuvant therapy
Chemotherapy 1 (4) 0 NA NA
Radiotherapy 0 14 (36) NA NA
Both 1 (4) 1 (3) NA NA
Abbreviations: NA, not applicable; NR, not reported.
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Figure 1 Median concentration and interquartile range of faecal tumour
M2-pyruvate kinase concentrations among CRC patients and among
ESTHER study participants.
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spatients. The prevalence of undiagnosed CRC in this age group has
been reported to be below 1% (Imperiale et al, 2000; Segnan et al,
2002). Model calculations showed that specificity increases from
73.0 to 73.3% and 73.5% assuming a prevalence of undiagnosed
CRC of 0, 0.5% and 1.0%, respectively (see Appendix B). Thus, the
resulting error (ie, an underestimation of specificity) should be
very small.
Another aspect that deserves more consideration is the potential
presence of adenomas among controls with ‘false’-positive test
result. Screening and autopsy studies found that the prevalence of
adenomas in this age group is about 30% (Vatn and Stalsberg,
1982; Winawer et al, 1988; Rex et al, 1993) and other studies
have reported a sensitivity of the tumour M2-PK test to detect
adenomas of about 30% (Koss et al, 2005; Shastri et al, 2006).
Model calculations showed that specificity increases from 73.0 to
74.7 and 79.0% assuming a sensitivity for adenomas of 30 and 40%,
respectively (and assuming a prevalence of adenomas and CRC of
30 and 0.5%, respectively; see Appendix B). These figures suggest
that specificity is likely to be slightly higher among subjects who
are endoscopically proven free of colorectal lesions.
So far, specificity of the tumour M2-PK test has only been
estimated based on selected high-risk controls (Hardt et al, 2004;
Shastri et al, 2006). Our results suggest that specificity may be
slightly higher in an asymptomatic screening population. Never-
theless, the false-positive rate of this test is still high and
possibilities to enhance specificity should be explored. Considering
Table 2 Performance characteristics of the tumour M2-PK stool test at a
cutoff value of 4Uml
 1 among patients with colorectal cancer
Sensitivity
Patient
group
Proportion of CRC
cases tested
positive (%)
95% confidence
interval
CRC 44/65 68 55–79
Colon 22/26 85 65–96
Rectum 22/39 56 41–74
Proximal
a 14/16 88 62–99
Distal
a 30/49 61 46–75
T1
b 4/6 67 22–96
T2
b 7/16 44 20–70
T3
b 24/34 71 53–85
T4
b 4/4 100 40–100
Dukes’ A 8/12 67 35–90
Dukes’ B 11/18 61 36–83
Dukes’ C 8/12 67 35–90
Dukes’ D 6/6 100 54–100
Neoadjuvant therapy
No 33/48 69 54–81
Yes 11/16 69 41–89
Abbreviations: CRC¼colorectal cancer.
aProximal / distal to the splenic flexure.
bT
stage according to the TNM classification.
Table 3 Distribution of subjects in the population sample (ESTHER study participants), and proportion of positive test results for faecal tumor M2-PK at a
cutoff value of 4Uml
 1 according to age, sex, body mass index, cigarette smoking status and family history of colorectal cancer
Proportion of ESTHER participants tested positive P-value (v
2 test) Specificity (95% CI)
196/917 21.4% 78.6% (75.8–81.2%)
Age group (years)
50–54 30/165 18.2%
55–59 34/150 22.7%
60–64 56/263 21.3%
65–69 42/194 21.6%
70–75 34/142 23.9% 0.789
Sex
Females 104/525 19.8%
Males 92/392 23.5% 0.181
Body mass index (kgm
 2)
p25 45/243 18.5%
425–30 78/398 19.6%
430 67/262 25.6% 0.097
Cigarette smoking status
Never smoker 98/484 20.2%
Former smoker 45/258 17.4%
Current smoker 48/154 31.2% 0.003
Family history of CRC
First degree relative with CRC 13/68 19.1%
No first degree relative with CRC 183/849 21.6% 0.637
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Figure 2 Receiver operating characteristics curve for the tumour M2-PK
stool test in detecting patients with CRC.
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sthe current specificity, it is debatable whether implementation of
this test in a population-based screening setting is justifiable, from
both an ethical and an economic point of view. However, while
awaiting the development of an optimal screening test, it may be
an option for individuals who wish a test with a higher sensitivity
than the FOBT (provided that high sensitivity is confirmed by
further studies) and who are well informed on possible false-
positive findings. Furthermore, as previous simulations have
shown (Haug and Brenner, 2005b), limited specificity in the long
run may reduce CRC incidence by ensuring that a large proportion
of screened subjects undergo colonoscopy even though more
focused and economic approaches to achieve this goal would be
highly desirable.
Apart from performance characteristics, this study was the first
to determine faecal tumour M2-PK concentrations in a large
sample of unselected older adults allowing investigation of
potential determinants of this stool marker. The lack of association
between important risk factors for CRC and increased levels of
tumour M2-PK suggests that tumour M2-PK is not a marker of
CRC risk, but the release of tumour M2-PK into the bowel is only
increased when neoplastic lesions are already present. The
observed association between current smoking status and higher
levels of tumour M2-PK necessitates further examination. Given
that the proportion of smokers was comparable among colon
cancer patients, rectal cancer patients and ESTHER participants in
our study, smoking status should not have confounded the
estimates of sensitivity and specificity.
As regards more practical aspects, the analytic procedure of
determining faecal tumour M2-PK is rather simple and inexpen-
sive compared with other novel approaches, for example, DNA-
based stool testing. Analyses are performed on only 4mg of stool,
and for sampling a special stick is used to capture the stool. On the
one hand, this sampling modality appears to be less unpleasant
than collecting a larger quantity of stool using a spatula or spoon,
an aspect that may improve compliance with screening. On the
other hand, given that the marker is determined quantitatively,
the approach might be prone to variability owing to incorrect
sampling. Considering the problem in a larger context, exact
analyses might be a particular challenge of protein-based markers,
where quantitative measurements are more common. In contrast,
DNA-based tests predominantly provide qualitative (yes/no)
answers.
In the interpretation of our results, the following limitations
should be kept in mind. Samples from cases and controls could not
be analysed in a blinded fashion. However, this may not have a
relevant impact given the highly standardised and automated
performance of this test. Another limitation concerns the
collection of stool samples, which was different for cases and
controls. To account for potential bias from this source, we
performed sensitivity analyses based on the results from stability
testing (Haug et al, 2006). These analyses showed that performance
characteristics of the test only changed slightly when potential
degradation during mailing of control samples was taken into
account. The consistency of our findings with performance
characteristics reported previously based on smaller sample sizes
(Hardt et al, 2004; Shastri et al, 2006) further supports that the
limitations of our study might not have distorted the results.
Given that previous studies on tumour M2-PK did not mention
conditions of sample handling at all (Hardt et al, 2004; Shastri
et al, 2006), the necessity of raising stability issues within our study
is not only a limitation, but also a strength and allows further
conclusion: Application of the test in a setting where a cold chain
might be feasible would be expected to result in levels of specificity
close to the corrected levels derived in this study and in levels
of sensitivity close to those observed in this study. Conversely,
application of the test in a setting where all stool samples are
mailed without cooling would be expected to result in levels of
specificity close to the uncorrected levels observed in this study
and in levels of sensitivity that would be somewhat lower than
observed in this study. The possibility of buffer-based stabilisation
of faecal tumour-M2-PK should be explored.
In conclusion, regarding the comparatively high sensitivity of
the tumour M2-PK stool test, its potential use for early detection of
CRC and adenomas merits further investigation. At the current
specificity, the test would result in a large proportion of follow-up
colonoscopies. Possibilities to enhance specificity of the test (eg, by
combination with other markers) need to be explored to make
potential screening based on this test more focused and economic.
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Appendix A
The following equation was used to estimate initial tumour M2-PK
concentrations among ESTHER study participants: Con0¼Coni/
relconi, where
Con0 denotes the initial concentration, Coni denotes the
concentration measured after i days of (uncooled) sample mailing
and relconi denotes the relative concentration after i days of
storage at room temperature as determined in a preceding stability
testing study (Haug et al, 2006).
Appendix B
To refine the estimated specificity of the tumour M2-PK test, the
following components were first calculated:
No. of controls testing positive: Npos¼N*Ppos
No. of controls with undiagnosed CRC: Ncrc¼N*Pcrc
No. of controls with adenomas: Nad¼N*Pad
No. of controls with undiagnosed CRC testing positive:
Ncrcpos ¼Ncrc *S E crc
No. of controls with adenomas testing positive: Nadpos ¼Nad*SEad
where, N denotes the whole number of controls, Ppos the
proportion of controls testing positive (positivity rate), Pcrc
and Pad denote the prevalence of undiagnosed CRC and
adenomas among controls, respectively, and SEcrc and SEad denote
the sensitivity of the test to detect CRC and adenomas,
respectively.
Inserting these components, specificity in terms of detecting
CRC (SPcrc, ie, healthy means not having CRC) and specificity in
terms of detecting adenomas (SPad, ie, healthy means having
neither CRC nor adenomas) were calculated as follows:
SPcrc ¼ 1  
Npos   Ncrcpos
N   Ncrc
SPad ¼ 1  
Npos   Ncrcpos   Nadpos
N   Ncrc   Nad
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